Literature DB >> 22981350

Nuclear survivin expression is associated with a poor prognosis in Caucasian non-small cell lung cancer patients.

Yu-Lan Xie1, Li An, Hao Jiang, Jing Wang.   

Abstract

BACKGROUND: The role of the nuclear protein survivin in non-small cell lung cancer (NSCLC) remains controversial. To clarify the association of survivin with survival in NSCLC, we performed a meta-analysis of the literature with meta-analysis.
METHODS: Trials were selected for further analysis if they provided an independent assessment of nuclear survivin in NSCLC and reported the survival data in the context of survivin status. A total of 7 trials, which comprised 823 patients, were included in the meta-analysis. Sensitivity analyses were conducted using the patient's disease stage, IHC cutoff value, and ethnicity.
RESULTS: The combined hazard ratio (HR) of 1.54 [95% CI, 0.79-3.02; test for heterogeneity p<0.001] suggests that high nuclear survivin expression has no impact on patient survival. However, when the studies were restricted to Caucasian patients, high levels of nuclear survivin expression were correlated with reduced survival (HR 2.38, 95% CI=1.60-3.52; p=0.189 for heterogeneity). In addition, the heterogeneity disappeared when the analysis was restricted to Caucasians.
CONCLUSION: Nuclear survivin expression is associated with poor prognosis for Caucasian NSCLC patients.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22981350     DOI: 10.1016/j.cca.2012.08.012

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Survivin expression in lung cancer: Association with smoking, histological types and pathological stages.

Authors:  Hiroshi Hirano; Hajime Maeda; Toshihiko Yamaguchi; Soichiro Yokota; Masahide Mori; Saburo Sakoda
Journal:  Oncol Lett       Date:  2015-06-16       Impact factor: 2.967

2.  BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.

Authors:  Zannel Blanchard; Bibbin T Paul; Barbara Craft; Wael M ElShamy
Journal:  Breast Cancer Res       Date:  2015-01-13       Impact factor: 6.466

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.